NEW YORK, Oct. 2 – Drug discovery company Pharmacopeia of Princeton, NJ, said Tuesday it has agreed to collaborate with German pharmaceutical company Boehringer Ingelheim to identify lead compounds for an undisclosed target.

Under the terms of the deal, Pharmacopeia will help Boehringer Ingelheim to develop assays and will provide the company with compound samples. In addition, Pharmacopeia will also provide high-throughput screening technology services.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.